EGFR TKIs耐药机制及其应对策略的研究进展

Research Progress on Mechanisms of Resistance and Treatment Approaches of EGFR-TKI

随着对肿瘤发病机制及其生物学行为的深入研究,分子靶向治疗成为目前治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)最具前景的研究领域。表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)可延长患者无进展生存期并明显提高患者生活质量,然而耐药已成为影响该类药物临床应用的最大障碍。全文就一代和三代EGFR-TKI的耐药机制与治疗策略的研究进展进行综述。

With deeper insights into the pathogenesis and biological behavior of cancer,molecular targeted therapy has become the most promising area in the studies of non-small cell lung cancer（NSCLC）.The epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI） significantly improves the quality of life and prolongs progression-free survival of the patients,but the resistance to EGFR-TKI has emerged as the biggest obstacle to its application.This article updates the mechanisms of the resistance and treatment approaches of first-generation and third-generation EGFR-TKIs.